Case report: Long-term efficacy and safety of semaglutide in the treatment of syndromic obesity in Prader Willi syndrome - case series and literature review
IntroductionPrader-Willi syndrome (PWS) is the most prevalent cause of syndromic obesity. Obesity development in PWS is driven by dysfunction in neural pathways involved in satiety and reward, dysregulation in hormones regulating satiety and food intake, altered body composition and reduced energy e...
Saved in:
Main Authors: | Andrijana Koceva, Katarina Mlekuš Kozamernik, Andrej Janež, Rok Herman, Simona Ferjan, Mojca Jensterle |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2025-01-01
|
Series: | Frontiers in Endocrinology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2024.1528457/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy and safety of once-weekly semaglutide monotherapy in a young subject with Prader-Willi syndrome, obesity, and type 2 diabetes: a case report
by: Elisa Dinoi, et al.
Published: (2025-02-01) -
Validation of the Food Safe Zone questionnaire for families of individuals with Prader-Willi syndrome
by: Elisabeth M. Dykens, et al.
Published: (2025-02-01) -
Three Siblings with Prader-Willi Syndrome: Brief Review of Sleep and Prader-Willi Syndrome
by: Arina Bingeliene, et al.
Published: (2015-01-01) -
The Effects of Oral Semaglutide on Hepatic Fibrosis in Subjects with Type 2 Diabetes in Real-World Clinical Practice: A Post Hoc Analysis of the Sapporo-Oral SEMA Study
by: Hiroya Kitsunai, et al.
Published: (2025-01-01) -
Prader-Willi Syndrome: Clinical Aspects
by: Grechi Elena, et al.
Published: (2012-01-01)